论文部分内容阅读
目的:研究采用米非司酮治疗子宫肌瘤时,米非司酮的用药剂量的大小与治疗效果的关系,得出治疗子宫肌瘤采用的米非司酮的合适剂量。方法:在2012年1月-12月这一年中,总共有498例子宫肌瘤患者入院进行治疗,从中随机抽取160例,平均非为两组,即对照组和观察组。对照组采用口服10.0mg的米非司酮进行治疗,观察组口服20.0mg的米非司酮进行治疗。在这160例患者进行治疗3个月后,检查两组患者的子宫肌瘤缩小幅度和子宫体积的变化,并记录在治疗过程中两组患者的不良反应发生情况,对记录结果进行对比,分析治疗效果。结果:两组患者的子宫肌瘤和子宫体均有明显的缩小,取得了一定的疗效,治疗效果相当,但就不良反应的发生情况来讲,对照组比观察组明显减少。结论:采用米非司酮治疗子宫肌瘤的合理剂量是10.0mg,治疗效果虽然没有很明显的不同,但是不良反应发生的现象很少,值得推广。
OBJECTIVE: To study the relationship between the dose of mifepristone and the therapeutic effect when using mifepristone in the treatment of uterine myoma, and to find out the appropriate dose of mifepristone for treating uterine fibroids. METHODS: During the January-December 2012 year, a total of 498 patients with uterine fibroids were admitted to hospital for treatment, and 160 patients were randomly selected from the two groups, ie, the control group and the observation group. The control group was orally administered with 10.0 mg of mifepristone, and the observation group was treated with 20.0 mg of mifepristone orally. After these 160 patients were treated for 3 months, the reduction of uterine fibroids and changes in uterine volume were examined in both groups. The incidence of adverse reactions in both groups was recorded during the course of treatment. The results were compared and analyzed treatment effect. Results: The two groups of patients with uterine fibroids and uterine body were significantly reduced, and achieved a certain effect, the treatment effect is quite, but the occurrence of adverse reactions, the control group was significantly reduced than the observation group. Conclusion: The reasonable dose of mifepristone for treating uterine fibroids is 10.0mg. Although there is no obvious difference in the therapeutic effect, there are few adverse reactions and it is worth popularizing.